Felix Masiye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Felix Masiye has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Emmanuela Gakidou
Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
7 shared publications Oliver Kaonga
Centre for Health Economics, University of York, Heslington, York, YO10 5DD, UK
5 shared publications- Chrispin Mphuka
Department of Economics, University of Zambia, PO Box 32379, Lusaka, Zambia
4 shared publications - Laura Dwyer-Lindgren
Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA
4 shared publications - Abraham D. Flaxman
Institute for Health Metrics and Evaluation, University of Washington
3 shared publications - Emelda A. Okiro
Population and Health Impact Surveillance Group, Kenya Medical Research Institute-Wellcome Trust Research Programme, Nairobi, Kenya
3 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (11) , e0007568
Experiences administering the EuroQol five-dimension five-level (EQ-5D-5L) for valuation of health-related quality of life estimates in Kenya: An embedded qualitative study
The EuroQol five-dimension five-level (EQ-5D-5L) instrument is increasingly used to develop health-state utility value sets for computing quality-adjusted life years (QALYs) in economic evaluations. However, little attention has been given to the practical realities of administering EQ-5D-5L valuation interviews in African settings. This study examined experiences of administering EQ-5D-5L valuation interviews in Kenya. We conducted an embedded qualitative study alongside the Kenyan EQ-5D-5L national valuation study. Data were collected through 23 post-valuation in-depth interviews with community participants and 16 debrief sessions with valuation interviewers and field supervisors. Post-valuation interviews were conducted in English or Kiswahili, audio-recorded, transcribed verbatim, translated where necessary, and analysed thematically. Health-state preferences were shaped by personal and contextual factors, including illness experience, household financial implications of ill health, beliefs about death, norms concerning independence and social worth, and local environmental conditions. Participants identified aspects of health they felt were not fully captured by the EQ-5D-5L descriptive system, namely vision, speech, broader aspects of mental health and social relationships. Pain/discomfort, mobility, and usual activities were often the most influential dimensions, while anxiety/ depression was generally given less weight. Tool-related linguistic and semantic challenges affected comprehension of some terms, while participant-related factors such as limited literacy, sensory difficulties and caregiving responsibilities also shaped administration. Valuation interviewers and field supervisors used strategies to preserve the intended logic of the valuation tasks, support participant comprehension, manage interruptions and protect data quality. Embedding qualitative methods within EQ-5D-5L valuation studies can complement standard quality-control procedures and quantitative valuation outputs by explaining how participants understood health states, what factors shaped their preferences, and whether administration challenges may have influenced responses. These insights can help researchers and decision-makers interpret final utility values by showing whether observed valuation patterns reflect locally meaningful preferences or challenges in understanding and completing valuation tasks.
- 4 November 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (11) , e0007568
Open AccessExperiences administering the EuroQol five-dimension five-level (EQ-5D-5L) for valuation of health-related quality of life estimates in Kenya: An embedded qualitative study
The EuroQol five-dimension five-level (EQ-5D-5L) instrument is increasingly used to develop health-state utility value sets for computing quality-adjusted life years (QALYs) in economic evaluations. However, little attention has been given to the practical realities of administering EQ-5D-5L valuation interviews in African settings. This study examined experiences of administering EQ-5D-5L valuation interviews in Kenya. We conducted an embedded qualitative study alongside the Kenyan EQ-5D-5L national valuation study. Data were collected through 23 post-valuation in-depth interviews with community participants and 16 debrief sessions with valuation interviewers and field supervisors. Post-valuation interviews were conducted in English or Kiswahili, audio-recorded, transcribed verbatim, translated where necessary, and analysed thematically. Health-state preferences were shaped by personal and contextual factors, including illness experience, household financial implications of ill health, beliefs about death, norms concerning independence and social worth, and local environmental conditions. Participants identified aspects of health they felt were not fully captured by the EQ-5D-5L descriptive system, namely vision, speech, broader aspects of mental health and social relationships. Pain/discomfort, mobility, and usual activities were often the most influential dimensions, while anxiety/ depression was generally given less weight. Tool-related linguistic and semantic challenges affected comprehension of some terms, while participant-related factors such as limited literacy, sensory difficulties and caregiving responsibilities also shaped administration. Valuation interviewers and field supervisors used strategies to preserve the intended logic of the valuation tasks, support participant comprehension, manage interruptions and protect data quality. Embedding qualitative methods within EQ-5D-5L valuation studies can complement standard quality-control procedures and quantitative valuation outputs by explaining how participants understood health states, what factors shaped their preferences, and whether administration challenges may have influenced responses. These insights can help researchers and decision-makers interpret final utility values by showing whether observed valuation patterns reflect locally meaningful preferences or challenges in understanding and completing valuation tasks.
- Open Access
- 24 September 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (9) , e0007080
Supply, demand and use of economic evidence in vaccine policymaking in Africa: A scoping review
Economic evaluation offers policy makers a valuable tool for optimizing the use scarce healthcare resources. This scoping review aims to describe the existing scientific literature on economic evaluation and budget impact analysis of vaccine interventions, and the use of economic evidence in Africa. It highlights the current landscape and the challenges in using economic data to support vaccine policy on the continent. This study adapted and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We included peer-reviewed studies published in English between January 2000 and July 2025 that reported on cost and economic evaluations of vaccines administered to children and youth, or on the use of economic evidence for policy decision-making in Africa. A literature search was conducted across five electronic databases: Medline, Embase, Web of Science, and Scopus. The search yielded 4037 articles in total after deduction of duplication. A total of 140 articles were included in the study following title, abstract screening and full text review. The review identified a sparse but growing literature of economic evaluations related to vaccine interventions in Africa. Only a handful of countries are represented in the articles published, implying a very low production of (and likely a low demand for) economic evaluation evidence. Authorship of the articles is led mostly by researchers from institutions based outside Africa, mostly in North America and Europe. Funding of studies is mostly by Gates Foundation, Gavi, PATH, Wellcome Trust and World Health Organisation. Production and use of economic evaluation for vaccine policy in Africa have been hampered by capacity limitations in both research and policy institutions on the continent. The use of the evidence in decision making is limited. In the sphere of vaccine policy, economic evaluation is still a fledging enterprise requiring more investment.
- 24 September 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (9) , e0007080
Open AccessSupply, demand and use of economic evidence in vaccine policymaking in Africa: A scoping review
Economic evaluation offers policy makers a valuable tool for optimizing the use scarce healthcare resources. This scoping review aims to describe the existing scientific literature on economic evaluation and budget impact analysis of vaccine interventions, and the use of economic evidence in Africa. It highlights the current landscape and the challenges in using economic data to support vaccine policy on the continent. This study adapted and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We included peer-reviewed studies published in English between January 2000 and July 2025 that reported on cost and economic evaluations of vaccines administered to children and youth, or on the use of economic evidence for policy decision-making in Africa. A literature search was conducted across five electronic databases: Medline, Embase, Web of Science, and Scopus. The search yielded 4037 articles in total after deduction of duplication. A total of 140 articles were included in the study following title, abstract screening and full text review. The review identified a sparse but growing literature of economic evaluations related to vaccine interventions in Africa. Only a handful of countries are represented in the articles published, implying a very low production of (and likely a low demand for) economic evaluation evidence. Authorship of the articles is led mostly by researchers from institutions based outside Africa, mostly in North America and Europe. Funding of studies is mostly by Gates Foundation, Gavi, PATH, Wellcome Trust and World Health Organisation. Production and use of economic evaluation for vaccine policy in Africa have been hampered by capacity limitations in both research and policy institutions on the continent. The use of the evidence in decision making is limited. In the sphere of vaccine policy, economic evaluation is still a fledging enterprise requiring more investment.
- Open Access
- 4 February 2023
- Published by Elsevier in Social Science & Medicine
- Vol. 321, 115750
Confidence in the health system and health insurance enrollment among the informal sector population in Lusaka, Zambia
- 4 February 2023
- Published by Elsevier in Social Science & Medicine
- Vol. 321, 115750
Open AccessConfidence in the health system and health insurance enrollment among the informal sector population in Lusaka, Zambia
- Open Access
- 16 November 2022
- Published by Springer Nature in Implementation Science
- Vol. 17 (1) , 1-10
Economic evaluation of implementation science outcomes in low- and middle-income countries: a scoping review
Background: Historically, the focus of cost-effectiveness analyses has been on the costs to operate and deliver interventions after their initial design and launch. The costs related to design and implementation of interventions have often been omitted. Ignoring these costs leads to an underestimation of the true price of interventions and biases economic analyses toward favoring new interventions. This is especially true in low- and middle-income countries (LMICs), where implementation may require substantial up-front investment. This scoping review was conducted to explore the topics, depth, and availability of scientific literature on integrating implementation science into economic evaluations of health interventions in LMICs. Methods: We searched Web of Science and PubMed for papers published between January 1, 2010, and December 31, 2021, that included components of both implementation science and economic evaluation. Studies from LMICs were prioritized for review, but papers from high-income countries were included if their methodology/findings were relevant to LMIC settings. Results: Six thousand nine hundred eighty-six studies were screened, of which 55 were included in full-text review and 23 selected for inclusion and data extraction. Most papers were theoretical, though some focused on a single disease or disease subset, including: mental health (n = 5), HIV (n = 3), tuberculosis (n = 3), and diabetes (n = 2). Manuscripts included a mix of methodology papers, empirical studies, and other (e.g., narrative) reviews. Authorship of the included literature was skewed toward high-income settings, with 22 of the 23 papers featuring first and senior authors from high-income countries. Of nine empirical studies included, no consistent implementation cost outcomes were measured, and only four could be mapped to an existing costing or implementation framework. There was also substantial heterogeneity across studies in how implementation costs were defined, and the methods used to collect them. Conclusion: A sparse but growing literature explores the intersection of implementation science and economic evaluation. Key needs include more research in LMICs, greater consensus on the definition of implementation costs, standardized methods to collect such costs, and identifying outcomes of greatest relevance. Addressing these gaps will result in stronger links between implementation science and economic evaluation and will create more robust and accurate estimates of intervention costs. Trial registration: The protocol for this manuscript was published on the Open Science Framework. It is available at: https://osf.io/ms5fa/ (DOI: 10.17605/OSF.IO/32EPJ).
- 16 November 2022
- Published by Springer Nature in Implementation Science
- Vol. 17 (1) , 1-10
Open AccessEconomic evaluation of implementation science outcomes in low- and middle-income countries: a scoping review
Background: Historically, the focus of cost-effectiveness analyses has been on the costs to operate and deliver interventions after their initial design and launch. The costs related to design and implementation of interventions have often been omitted. Ignoring these costs leads to an underestimation of the true price of interventions and biases economic analyses toward favoring new interventions. This is especially true in low- and middle-income countries (LMICs), where implementation may require substantial up-front investment. This scoping review was conducted to explore the topics, depth, and availability of scientific literature on integrating implementation science into economic evaluations of health interventions in LMICs. Methods: We searched Web of Science and PubMed for papers published between January 1, 2010, and December 31, 2021, that included components of both implementation science and economic evaluation. Studies from LMICs were prioritized for review, but papers from high-income countries were included if their methodology/findings were relevant to LMIC settings. Results: Six thousand nine hundred eighty-six studies were screened, of which 55 were included in full-text review and 23 selected for inclusion and data extraction. Most papers were theoretical, though some focused on a single disease or disease subset, including: mental health (n = 5), HIV (n = 3), tuberculosis (n = 3), and diabetes (n = 2). Manuscripts included a mix of methodology papers, empirical studies, and other (e.g., narrative) reviews. Authorship of the included literature was skewed toward high-income settings, with 22 of the 23 papers featuring first and senior authors from high-income countries. Of nine empirical studies included, no consistent implementation cost outcomes were measured, and only four could be mapped to an existing costing or implementation framework. There was also substantial heterogeneity across studies in how implementation costs were defined, and the methods used to collect them. Conclusion: A sparse but growing literature explores the intersection of implementation science and economic evaluation. Key needs include more research in LMICs, greater consensus on the definition of implementation costs, standardized methods to collect such costs, and identifying outcomes of greatest relevance. Addressing these gaps will result in stronger links between implementation science and economic evaluation and will create more robust and accurate estimates of intervention costs. Trial registration: The protocol for this manuscript was published on the Open Science Framework. It is available at: https://osf.io/ms5fa/ (DOI: 10.17605/OSF.IO/32EPJ).
- Open Access
- 13 November 2022
- Published by International Society of Global Health in Journal of Global Health Economics and Policy
- Vol. 2
The present value of human life losses associated with COVID-19 in South Africa
Background: Coronavirus disease (COVID-19) continues to ravage both the health and economy of South Africa. This study estimated the total present value of human life (TPVHL) losses associated with COVID-19 in South Africa. Methods: The human capital approach (HCA) was used to value the 101,146 human life losses associated with COVID-19 in South Africa as of 30 May 2022 – assuming South Africa’s average life expectancy of 64.88 years and a 3% discount rate. The TPVHL was the sum of discounted values of human life (VHL) across the 17 age groups. The PVHL for each age group is the product of the sum of discounted years of life lost per person, gross domestic product per capita net of current health expenditure per person, and the number of COVID-19 deaths borne by a specific age group. During sensitivity analysis, the HCA model was reanalysed four times alternately, assuming a 5% discount rate, 10% discount rate, Africa’s highest average life expectancy of 78.76 years (Algeria females), and the world’s highest life expectancy of 88.17 years (Hong Kong females). Results: The 101,146 human lives lost had a TPVHL of Int$7,566,656,063, and an average of Int$74,809 per human life lost to COVID-19. Subsequent re-calculation of the model with a 5% and 10% discount rates diminished the TPVHL by Int$1,177,446,403 (15.6%) and Int$2,997,459,371 (39.6%), respectively. Further, a reanalysis of the model with Africa’s highest average life expectancy and the world’s highest life expectancy triggered growth in the TPVHL of Int$8,846,142,813 (116.9%) and Int$15,363,165,669 (203.04%), respectively. Conclusions: The average discounted value per human life lost to COVID-19 of Int$74,809 is five-fold the GDP per capita for South Africa in 2022, setting the country back a few years in terms of socio-economic development. Thus, COVID-19 continues to have a significant negative impact on the life and livelihoods of South Africans. The economic evidence complements the human rights case for increased domestic investment into health-related systems to bridge the gaps in coverage of health development-related services.
- 13 November 2022
- Published by International Society of Global Health in Journal of Global Health Economics and Policy
- Vol. 2
Open AccessThe present value of human life losses associated with COVID-19 in South Africa
Background: Coronavirus disease (COVID-19) continues to ravage both the health and economy of South Africa. This study estimated the total present value of human life (TPVHL) losses associated with COVID-19 in South Africa. Methods: The human capital approach (HCA) was used to value the 101,146 human life losses associated with COVID-19 in South Africa as of 30 May 2022 – assuming South Africa’s average life expectancy of 64.88 years and a 3% discount rate. The TPVHL was the sum of discounted values of human life (VHL) across the 17 age groups. The PVHL for each age group is the product of the sum of discounted years of life lost per person, gross domestic product per capita net of current health expenditure per person, and the number of COVID-19 deaths borne by a specific age group. During sensitivity analysis, the HCA model was reanalysed four times alternately, assuming a 5% discount rate, 10% discount rate, Africa’s highest average life expectancy of 78.76 years (Algeria females), and the world’s highest life expectancy of 88.17 years (Hong Kong females). Results: The 101,146 human lives lost had a TPVHL of Int$7,566,656,063, and an average of Int$74,809 per human life lost to COVID-19. Subsequent re-calculation of the model with a 5% and 10% discount rates diminished the TPVHL by Int$1,177,446,403 (15.6%) and Int$2,997,459,371 (39.6%), respectively. Further, a reanalysis of the model with Africa’s highest average life expectancy and the world’s highest life expectancy triggered growth in the TPVHL of Int$8,846,142,813 (116.9%) and Int$15,363,165,669 (203.04%), respectively. Conclusions: The average discounted value per human life lost to COVID-19 of Int$74,809 is five-fold the GDP per capita for South Africa in 2022, setting the country back a few years in terms of socio-economic development. Thus, COVID-19 continues to have a significant negative impact on the life and livelihoods of South Africans. The economic evidence complements the human rights case for increased domestic investment into health-related systems to bridge the gaps in coverage of health development-related services.
- Open Access
- 13 November 2022
- Published by International Society of Global Health in Journal of Global Health Economics and Policy
- Vol. 2, e2022017
The present value of human life losses associated with COVID-19 in South Africa
Background: Coronavirus disease (COVID-19) continues to ravage both the health and economy of South Africa. This study estimated the total present value of human life (TPVHL) losses associated with COVID-19 in South Africa. Methods: The human capital approach (HCA) was used to value the 101,146 human life losses associated with COVID-19 in South Africa as of 30 May 2022 – assuming South Africa’s average life expectancy of 64.88 years and a 3% discount rate. The TPVHL was the sum of discounted values of human life (VHL) across the 17 age groups. The PVHL for each age group is the product of the sum of discounted years of life lost per person, gross domestic product per capita net of current health expenditure per person, and the number of COVID-19 deaths borne by a specific age group. During sensitivity analysis, the HCA model was reanalysed four times alternately, assuming a 5% discount rate, 10% discount rate, Africa’s highest average life expectancy of 78.76 years (Algeria females), and the world’s highest life expectancy of 88.17 years (Hong Kong females). Results: The 101,146 human lives lost had a TPVHL of Int$7,566,656,063, and an average of Int$74,809 per human life lost to COVID-19. Subsequent re-calculation of the model with a 5% and 10% discount rates diminished the TPVHL by Int$1,177,446,403 (15.6%) and Int$2,997,459,371 (39.6%), respectively. Further, a reanalysis of the model with Africa’s highest average life expectancy and the world’s highest life expectancy triggered growth in the TPVHL of Int$8,846,142,813 (116.9%) and Int$15,363,165,669 (203.04%), respectively. Conclusions: The average discounted value per human life lost to COVID-19 of Int$74,809 is five-fold the GDP per capita for South Africa in 2022, setting the country back a few years in terms of socio-economic development. Thus, COVID-19 continues to have a significant negative impact on the life and livelihoods of South Africans. The economic evidence complements the human rights case for increased domestic investment into health-related systems to bridge the gaps in coverage of health development-related services.
- 13 November 2022
- Published by International Society of Global Health in Journal of Global Health Economics and Policy
- Vol. 2, e2022017
Open AccessThe present value of human life losses associated with COVID-19 in South Africa
Background: Coronavirus disease (COVID-19) continues to ravage both the health and economy of South Africa. This study estimated the total present value of human life (TPVHL) losses associated with COVID-19 in South Africa. Methods: The human capital approach (HCA) was used to value the 101,146 human life losses associated with COVID-19 in South Africa as of 30 May 2022 – assuming South Africa’s average life expectancy of 64.88 years and a 3% discount rate. The TPVHL was the sum of discounted values of human life (VHL) across the 17 age groups. The PVHL for each age group is the product of the sum of discounted years of life lost per person, gross domestic product per capita net of current health expenditure per person, and the number of COVID-19 deaths borne by a specific age group. During sensitivity analysis, the HCA model was reanalysed four times alternately, assuming a 5% discount rate, 10% discount rate, Africa’s highest average life expectancy of 78.76 years (Algeria females), and the world’s highest life expectancy of 88.17 years (Hong Kong females). Results: The 101,146 human lives lost had a TPVHL of Int$7,566,656,063, and an average of Int$74,809 per human life lost to COVID-19. Subsequent re-calculation of the model with a 5% and 10% discount rates diminished the TPVHL by Int$1,177,446,403 (15.6%) and Int$2,997,459,371 (39.6%), respectively. Further, a reanalysis of the model with Africa’s highest average life expectancy and the world’s highest life expectancy triggered growth in the TPVHL of Int$8,846,142,813 (116.9%) and Int$15,363,165,669 (203.04%), respectively. Conclusions: The average discounted value per human life lost to COVID-19 of Int$74,809 is five-fold the GDP per capita for South Africa in 2022, setting the country back a few years in terms of socio-economic development. Thus, COVID-19 continues to have a significant negative impact on the life and livelihoods of South Africans. The economic evidence complements the human rights case for increased domestic investment into health-related systems to bridge the gaps in coverage of health development-related services.
- 26 May 2022
- Published by Elsevier in Social Science & Medicine
- Vol. 305, 115063
How viable is social health insurance for financing health in Zambia? Results from a national willingness to pay survey
- 26 May 2022
- Published by Elsevier in Social Science & Medicine
- Vol. 305, 115063
How viable is social health insurance for financing health in Zambia? Results from a national willingness to pay survey
- Open Access
- 1 December 2020
- Published by Elsevier in Health Policy OPEN
- Vol. 1, 100020
Informal payments for primary health services in Zambia: Evidence from a health facility patient exit survey
- 1 December 2020
- Published by Elsevier in Health Policy OPEN
- Vol. 1, 100020
Open AccessInformal payments for primary health services in Zambia: Evidence from a health facility patient exit survey
- Open Access
- 10 April 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (4) , e0214750
Hardship financing of out-of-pocket payments in the context of free healthcare in Zambia
Despite the removal of user fees on public primary healthcare in Zambia, prior studies suggest that out-of-pocket payments are still significant. However, we have little understanding of the extent to which out-of-pocket payments lead patients to hardship methods of financing out-of-pocket costs. This study analyses the prevalence and determinants of hardship financing arising from out-of-pocket payments in healthcare, using data from a nationally-representative household health expenditure survey conducted in 2014. We employ a sequential logistic regression model to examine the factors associated with the risk of hardship financing conditional on reporting an illness and an out-of-pocket expenditure. The results show that up to 11% of households who reported an illness had borrowed money, or sold items or asked a friend for help, or displaced other household consumption in order to pay for health care. The risk of hardship financing was higher among the poorest households, female headed-households and households who reside further from health facilities. Improvements in physical access and quality of public health services have the potential to reduce the incidence of hardship financing especially among the poorest.
- 10 April 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (4) , e0214750
Open AccessHardship financing of out-of-pocket payments in the context of free healthcare in Zambia
Despite the removal of user fees on public primary healthcare in Zambia, prior studies suggest that out-of-pocket payments are still significant. However, we have little understanding of the extent to which out-of-pocket payments lead patients to hardship methods of financing out-of-pocket costs. This study analyses the prevalence and determinants of hardship financing arising from out-of-pocket payments in healthcare, using data from a nationally-representative household health expenditure survey conducted in 2014. We employ a sequential logistic regression model to examine the factors associated with the risk of hardship financing conditional on reporting an illness and an out-of-pocket expenditure. The results show that up to 11% of households who reported an illness had borrowed money, or sold items or asked a friend for help, or displaced other household consumption in order to pay for health care. The risk of hardship financing was higher among the poorest households, female headed-households and households who reside further from health facilities. Improvements in physical access and quality of public health services have the potential to reduce the incidence of hardship financing especially among the poorest.
- Open Access
- 13 August 2018
- Published by Springer Nature in Population Health Metrics
- Vol. 16 (1) , 1-15
Small area estimation of under-5 mortality in Bangladesh, Cameroon, Chad, Mozambique, Uganda, and Zambia using spatially misaligned data
The under-5 mortality rate (U5MR) is an important metric of child health and survival. Country-level estimates of U5MR are readily available, but efforts to estimate U5MR subnationally have been limited, in part, due to spatial misalignment of available data sources (e.g., use of different administrative levels, or as a result of historical boundary changes). We analyzed all available complete and summary birth history data in surveys and censuses in six countries (Bangladesh, Cameroon, Chad, Mozambique, Uganda, and Zambia) at the finest geographic level available in each data source. We then developed small area estimation models capable of incorporating spatially misaligned data. These small area estimation models were applied to the birth history data in order to estimate trends in U5MR from 1980 to 2015 at the second administrative level in Cameroon, Chad, Mozambique, Uganda, and Zambia and at the third administrative level in Bangladesh. We found substantial variation in U5MR in all six countries: there was more than a two-fold difference in U5MR between the area with the highest rate and the area with the lowest rate in every country. All areas in all countries experienced declines in U5MR between 1980 and 2015, but the degree varied both within and between countries. In Cameroon, Chad, Mozambique, and Zambia we found areas with U5MRs in 2015 that were higher than in other parts of the same country in 1980. Comparing subnational U5MR to country-level targets for the Millennium Development Goals (MDG), we find that 12.8% of areas in Bangladesh did not meet the country-level target, although the country as whole did. A minority of areas in Chad, Mozambique, Uganda, and Zambia met the country-level MDG targets while these countries as a whole did not. Subnational estimates of U5MR reveal significant within-country variation. These estimates could be used for identifying high-need areas and positive deviants, tracking trends in geographic inequalities, and evaluating progress towards international development targets such as the Sustainable Development Goals.
- 13 August 2018
- Published by Springer Nature in Population Health Metrics
- Vol. 16 (1) , 1-15
Open AccessSmall area estimation of under-5 mortality in Bangladesh, Cameroon, Chad, Mozambique, Uganda, and Zambia using spatially misaligned data
The under-5 mortality rate (U5MR) is an important metric of child health and survival. Country-level estimates of U5MR are readily available, but efforts to estimate U5MR subnationally have been limited, in part, due to spatial misalignment of available data sources (e.g., use of different administrative levels, or as a result of historical boundary changes). We analyzed all available complete and summary birth history data in surveys and censuses in six countries (Bangladesh, Cameroon, Chad, Mozambique, Uganda, and Zambia) at the finest geographic level available in each data source. We then developed small area estimation models capable of incorporating spatially misaligned data. These small area estimation models were applied to the birth history data in order to estimate trends in U5MR from 1980 to 2015 at the second administrative level in Cameroon, Chad, Mozambique, Uganda, and Zambia and at the third administrative level in Bangladesh. We found substantial variation in U5MR in all six countries: there was more than a two-fold difference in U5MR between the area with the highest rate and the area with the lowest rate in every country. All areas in all countries experienced declines in U5MR between 1980 and 2015, but the degree varied both within and between countries. In Cameroon, Chad, Mozambique, and Zambia we found areas with U5MRs in 2015 that were higher than in other parts of the same country in 1980. Comparing subnational U5MR to country-level targets for the Millennium Development Goals (MDG), we find that 12.8% of areas in Bangladesh did not meet the country-level target, although the country as whole did. A minority of areas in Chad, Mozambique, Uganda, and Zambia met the country-level MDG targets while these countries as a whole did not. Subnational estimates of U5MR reveal significant within-country variation. These estimates could be used for identifying high-need areas and positive deviants, tracking trends in geographic inequalities, and evaluating progress towards international development targets such as the Sustainable Development Goals.